Product name | Linaclotide |
CAS No. | 851199-59-2 |
Molecular Formula | C59H79N15O21S6 |
Molecular Weight | 1526.736 g/mol |
Quality Standard | 98% up, Medicine Grade |
Appearance | White powder |
Sequence | H-Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr-OH cyclic(1-6),(2-10),(5-13)-tris(disulfide) |
Test | Specifications |
Appearance | White or almost white crystalline powder |
Identity by HPLC | The reaction is same with the reference substance |
Amino Acid Composition | ±20% of theoretical |
Purity (HPLC) | ≥ 98.0% |
Related Substance(By HPLC) | Total Impurities(%)≤ 2.0%
Largest Single Impurity(%)≤ 1.0% |
Acetate Content(By HPLC) | ≤15% |
Water Content(By HPLC) | ≤5.0% |
Bacterial Endotoxins | ≤5IU/mg |
Function of Linaclotide
Linaclotide can bind to the guanylate cyclase C-type receptor (GC-C) in the intestinal tract after being taken orally into the human body to increase the intracellular and extracellular cyclic guanylic acid (cGMP) concentration and stimulate the secretion of intestinal juice , To accelerate the migration of the gastrointestinal tract, thereby increasing the frequency of bowel movements. Due to its unique mechanism of action, it is promising to become a therapeutic drug that can not only treat constipation, but also treat abdominal distension, abdominal pain and other clinical symptoms.
